The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

• Published in: Scientific reports Vol. 12; no. 1; p. 8121
• Main Authors: Sakamoto, Kotaro, Lin, Bangzhong, Nunomura, Kazuto, Izawa, Takeshi, Nakagawa, Shinsaku
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 17.05.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154; 631/154/1438; 631/154/436; 631/154/556; 631/154/570; 631/67; 631/67/1059; 631/67/1504; 631/67/395; Animals; Antitumor activity; Apoptosis; CD8 antigen; Cell death; Cell Line, Tumor; Cell Proliferation; Clinical trials; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Drug delivery; Humanities and Social Sciences; K-Ras protein; Lung cancer; Metastases; Mice; Monoclonal antibodies; multidisciplinary; Mutant Proteins - genetics; Mutants; Mutation; Pancreatic cancer; PD-1 protein; PD-L1 protein; Peptides; Peptides - therapeutic use; Phosphorylation; Proto-Oncogene Proteins p21(ras) - genetics; Regulatory approval; Science; Science (multidisciplinary); Tumors; Xenografts

Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great clinical potential. Very recently, a drug targeting the K-Ras(G12C) mutant observed in lung cancer gained regulatory approval and several clinical t...